관절내 점성보충 시장 : 종류별, 연령층별, 판매 채널별, 용도별, 최종 용도별, 지역별(2026-2034년)

The global viscosupplementation market size reached USD 5.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 9.4 Billion by 2034, exhibiting a growth rate (CAGR) of 6.77% during 2026-2034.The increasing prevalence of osteoporosis and osteoarthritis (OA) and the shifting consumer inclination toward minimally invasive non-surgical treatments represent some of the key factors driving the market.

Viscosupplementation represents a minimally invasive medical procedure wherein intraarticular injection comprising gel-like fluid known as exogenous hydraulic acid (HA) derivatives are directly administered into the knee joints of the patient. It acts as a lubricant, which enables bones to move smoothly over each other, lowers inflammation, and performs as a shock absorber for joint loads. Viscosupplementation reduces the friction during the movements, assists the synovial fluids in creating more cushion, eliminates severe pain, and enhances the range of movements or motions of the joint. Apart from this, it restores the rheological properties of the synovial fluids, which produce mechanical, analgesic, anti-inflammatory, and chondroprotective effects. As a result, viscosupplementation is extensively utilized in the treatment of knee, hip, and hand osteoarthritis. Currently, it is mainly available in intermediate, low, and high molecular weights.

Viscosupplementation Market Trends:

The increasing prevalence of osteoporosis and osteoarthritis (OA) represents one of the key factors driving the market growth. In line with this, the shifting consumer inclination toward the minimally invasive non-surgical treatment options has facilitated the widespread adoption of viscosupplementation in the healthcare sector for corticosteroids and joint pain management. This, in turn, is acting as another major growth-inducing factor. This is further influenced by the growing consumer awareness regarding the multiple benefits of non-surgical treatments, including no hospitalization, fewer expenses, minimal complications, and better clinical outcomes and recovery rates. Additionally, the favorable government initiatives and significant investments by various pharmaceutical companies to launch novel drugs and different routes of administrations is supporting the market growth. Moreover, the emergence of ambulatory surgical centers (ACS) that offer intensive treatment to resolve surgical and non-surgical problems in various body parts, such as joints, ligaments, muscle, spine, and nerves, is favoring the market growth. Furthermore, the introduction of open-label single-injections with hydraulic acid is propelling the market growth. Apart from this, favorable health insurance reimbursement policies, the rising geriatric population, which is susceptible to chronic ailments, increasing number of individuals with chronic disability, collaborations and partnership among the key players, and continuous research and development (R&D) activities in the field of medical sciences are positively impacting the market growth.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the global viscosupplementation market, along with forecasts at the global, regional, and country level from 2026-2034. Our report has categorized the market based on type, age group, distribution channel, application and end use.

Type Insights:

• Single Injection
• Three Injection
• Five Injection

The report has also provided a detailed breakup and analysis of viscosupplementation market based on the type. This includes single, three and five injection. According to the report, single injection represented the largest segment.

Age Group Insights:

• Adults
• Geriatrics

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

The report has also provided a detailed breakup and analysis of viscosupplementation market based on the distribution channel. This includes hospital, retail and online pharmacies. According to the report, hospital pharmacies represented the largest segment.

Application Insights:

• Knee Osteoarthritis
• Hip Osteoarthritis
• Hand Osteoarthritis
• Others

End Use Insights:

• Hospitals
• Orthopedic Clinics
• Others

The report has also provided a detailed breakup and analysis of viscosupplementation market based on the end use. This includes hospitals, orthopedic clinics, and others. According to the report, orthopedic clinics represented the largest segment.

Regional Insights:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, the North America was the largest market for viscosupplementation. Some of the factors driving the North America viscosupplementation market included the rising geriatric population and the affordable health insurance reimbursement policies.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global viscosupplementation market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Anika Therapeutics Inc., Aptissen S.A., Bioventus LLC, Ferring Pharmaceuticals, Fidia Farmaceutici S.p.A., Johnson & Johnson, LG Chem Ltd., OrthogenRx Inc. (Avanos Medical Inc.), Sanofi S.A., Seikagaku Corporation, Virchow Biotech Private Limited, Zimmer Biomet, Zuventus HealthCare Ltd. (Emcure Pharmaceuticals Limited), etc.

Key Questions Answered in This Report:

• How has the global viscosupplementation market performed so far and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global viscosupplementation market?
• What are the key regional markets?
• Which countries represent the most attractive viscosupplementation markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the age group?
• What is the breakup of the market based on the distribution channel?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the end use?
• What is the competitive structure of the global viscosupplementation market?
• Who are the key players/companies in the global viscosupplementation market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Viscosupplementation Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Single Injection
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Three Injection
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Five Injection
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Age Group

• 7.1 Adults
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Geriatrics
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Pharmacies
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Application

• 9.1 Knee Osteoarthritis
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Hip Osteoarthritis
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Hand Osteoarthritis
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by End Use

• 10.1 Hospitals
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Orthopedic Clinics
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Others
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 Drivers, Restraints, and Opportunities

• 12.1 Overview
• 12.2 Drivers
• 12.3 Restraints
• 12.4 Opportunities

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Anika Therapeutics Inc.
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Aptissen S.A.
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
  • 16.3.3 Bioventus LLC
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
    • 16.3.3.3 Financials
  • 16.3.4 Ferring Pharmaceuticals
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
  • 16.3.5 Fidia Farmaceutici S.p.A.
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
  • 16.3.6 Johnson & Johnson
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 Financials
    • 16.3.6.4 SWOT Analysis
  • 16.3.7 LG Chem Ltd.
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 OrthogenRx Inc. (Avanos Medical Inc.)
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
  • 16.3.9 Sanofi S.A.
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 Financials
    • 16.3.9.4 SWOT Analysis
  • 16.3.10 Seikagaku Corporation
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
    • 16.3.10.3 Financials
  • 16.3.11 Virchow Biotech Private Limited
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
  • 16.3.12 Zimmer Biomet
    • 16.3.12.1 Company Overview
    • 16.3.12.2 Product Portfolio
    • 16.3.12.3 Financials
    • 16.3.12.4 SWOT Analysis
  • 16.3.13 Zuventus HealthCare Ltd. (Emcure Pharmaceuticals Limited)
    • 16.3.13.1 Company Overview
    • 16.3.13.2 Product Portfolio